INTRAVENOUS IMMUNOGLOBULIN IN THE TREATMENT OF JUVENILE RETINITIS PIGMENTOSA-ASSOCIATED CYSTOID MACULAR EDEMA AND UVEITIS.
OBJECTIVE
To evaluate the efficacy of intravenous immunoglobulin in the treatment of cystoid macular edema and uveitis caused by juvenile retinitis pigmentosa in a woman interested in planning a pregnancy.


METHODS
Descriptive case report. A 25-year-old woman with retinitis pigmentosa presented with decreased visual acuity, interested in a second opinion.


RESULTS
Intravenous immunoglobulin therapy was begun at 2-week intervals. Visual acuity improved from 20/100 to 20/70 by 6 weeks, where it stabilized for the remaining year. Serial optical coherence tomography imaging revealed marked improvement in cystoid macular edema after 2 treatments of intravenous immunoglobulin at 2 weeks of follow-up, with complete resolution noted at 4 months, a finding that persisted at 1 year of follow-up.


CONCLUSIONS
Our findings support the use of intravenous immunoglobulin as a therapeutic option for the resolution of cystoid macular edema and management of uveitis secondary to juvenile retinitis pigmentosa.
Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Lilangi S
LS
Ediriwickrema
Department of Ophthalmology, Miller School of Medicine, University of Miami, Miami, Florida.
Priyanka
P
Chhadva
Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Damien C
DC
Rodger
Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Hossein
H
Ameri
Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Narsing A
NA
Rao
D000328:Adult; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008269:Macular Edema / Q000188:drug therapy*; D012174:Retinitis Pigmentosa / Q000188:drug therapy*; D016896:Treatment Outcome; D014605:Uveitis / Q000188:drug therapy*
D016756:Immunoglobulins, Intravenous